PSA launches training for extended supply of oral contraceptive

7 September 2023


This Women’s Health Week the Pharmaceutical Society of Australia (PSA) has launched the NSW – Contraception Essentials training as onboarding begins for the next stage of the New South Wales Pharmacy Trial.


The statewide trial, run by the University of Newcastle, authorises pharmacists participating in the trial to continue a prescription for the resupply of a certain oral contraceptives for eligible women aged from 18 to 35 years.


Pharmacists must meet specific requirements to be eligible for participation, and completing the appropriate training is mandatory.


PSA New South Wales President Luke Kelly FPS urged pharmacists to complete their training with PSA ahead of the trial’s start date.


“Improving safe access to contraception is essential to improving health care for all Australians,” Mr Kelly said.


“PSA is proud to be leading the way in pharmacist education and supporting the development of pharmacy scope of practice.


“PSA has developed a comprehensive training course tailored to the NSW oral contraceptive trial, arming pharmacists with the latest clinical information and giving them the skills and knowledge for the continuation of appropriate contraception.


“This is about making sure that Australians can access contraception when and where they need it,” Mr Kelly concluded.


NSW Pharmacists can enrol in the NSW – Contraception Essentials training program here.


For more information on the NSW Pharmacy Trial, visit NSW Health.



Media contact:   Georgia Clarke   M: 0480 099 798  E: georgia.clarke@psa.org.au

Updated treatment guidelines for salbutamol and terbutaline

7 September 2023


Marking National Asthma Awareness Week (1-7 September), the Pharmaceutical Society of Australia (PSA) has launched updated treatment guidelines for pharmacists supplying salbutamol and terbutaline inhalers to patients suffering from asthma.


The updated treatment guidelines reflect the new Professional Practice Standards and include updated information about over reliance on short-acting beta2-agonists (SABA).


PSA National President Dr Fei Sim FPS says pharmacists have an increasingly important role to play in supporting patients to move away from relievers and toward preventers.


“Around 2.7 million or 11 per cent of Australians suffer from asthma, with PBS data indicating a growing reliance on relievers as treatment,” Dr Sim said.


“Over reliance on SABA relievers can increase the risk of severe asthma flare-ups and reduce the effectiveness of emergency treatments.


“The updated treatment guidelines support pharmacists to identify when it is appropriate to supply reliever inhalers to patients, and when their asthma may not be appropriately controlled.


“The guidelines also reinforce the importance of checking asthma symptom control, adherence, and inhaler technique at every opportunity.


“As the most accessible healthcare practitioners, community pharmacists are well placed to play a greater role in patient education and awareness of asthma-related harms, identify opportunity for clinical intervention and improve the safe and effective use of inhalers. When undertaking complex medication reviews, credentialled pharmacists are also best placed to make recommendations to optimise the use of treatments and management of asthma.


“We all have a role to play to encourage patients requesting SABA relievers to visit their medical practitioner to review their condition and make sure that they are receiving appropriate long-term care.”


PSA is urging all pharmacists to familiarise themselves with the updated guidelines, available at Australian Pharmaceutical Formulary and Handbook | Australian Pharmaceutical Formulary and Handbook (psa.org.au)


Media contact:   Georgia Clarke   M: 0480 099 798  E: georgia.clarke@psa.org.au

3,000 lives saved in first year of Take-Home Naloxone program

31 August 2023


This International Overdose Awareness Day, the Pharmaceutical Society of Australia (PSA) recognises the important role pharmacists play in supporting patients taking prescription opioids, noting that in its first year alone, the Take Home Naloxone (THN) program has saved 3000 lives.


The national THN program provides naloxone to anyone who may experience, or witness, an opioid overdose or adverse reaction for free and without a prescription.


Since the THN program began on 1 July 2022, an estimated 3,000 doses have been used by Australians experiencing or witnessing an opioid overdose or adverse reaction equating to 8 uses per day.


PSA National President Dr Fei Sim FPS says that pharmacists have been key to the success of the program because of their accessibility and expertise.


“The Take Home Naloxone program has saved Australian lives,” Dr Sim said.


“Evidence from the first year of the THN program shows that pharmacists are well-placed to provide naloxone, whether alongside a prescribed opioid or as a stand-alone supply.


“As our most accessible healthcare professionals, pharmacists have distributed over 90% of naloxone for the THN Program. This is evidence that pharmacist-provided naloxone as one of the harm minimisation initiatives, alongside counselling, is feasible and acceptable by Australians.


“To ensure ongoing sustainability and impact, pharmacists must be empowered and supported to provide this life-saving service.


“We are urging anyone taking opioids for pain management, or caring for someone who does, to have a conversation with your local pharmacist about having naloxone on-hand. We can also provide advice about identifying an opioid overdose and how to respond during an emergency.


“Over recent years we have seen more cases of illicit party drugs being spiked with acetyl-fentanyl which can cause opioid overdoses even in small amounts.


“Your pharmacist is there to provide judgement-free, expert advice on when and how to use this life-saving drug.


“It could save your life, or the life of a friend.”


Take Home Naloxone is available to Australians through their local pharmacist. PSA recommends calling ahead to ensure your local pharmacy participates in the THN program and has available stock.


Key facts:

  • Up to 8 lives saved each day from use of Take-Home Naloxone
  • Over 110,000 Australians are currently struggling with opioid dependence
  • 7% of unintentional drug-induced deaths in 2021 involved opioids



Media contact:   Georgia Clarke   M: 0480 099 798  E: georgia.clarke@psa.org.au


Data from 1 July 2022 to 30 June 2023, provided by the Department of Health and Aged Care.

Penington Institute Australia Annual Overdose Report 2023

Overdose report shows more needs to be done

28 August 2023


The Pharmaceutical Society of Australia (PSA) is calling for governments, health workers and support organisations to work together to do more to tackle the ongoing challenge of deaths caused by intentional and unintentional drug overdose. 


The Penington Institute’s Annual Overdose Report, released today, found there were 2,231 unintentional drug-induced deaths in Australia in 2021. Opioids and benzodiazepines were among the most common drugs involved in accidental overdose deaths.  


The report showed more than two-thirds of all unintentional drug-induced deaths involved two or more drug types (72.5%), with presence of benzodiazepines (such as diazepam, lorazepam and alprazolam) increasingly implicated in unintentional drug-induced deaths.  Anti-depressants (38%), stimulants (35%), and alcohol (25%) were also observed in unintentional deaths with two or more drug types.  


PSA National President Dr Fei Sim FPS said the report was a sobering reminder of the work still to be done to prevent avoidable harm from drug, including prescription medicines.  


“More Australians are using more medicines than ever before, and prescribing of multiple medicines to manage health conditions is increasingly common,” Dr Sim said. “However, some drug-drug combinations dramatically increase risk of unintentional drug-related death or hospitalisation, as this data tragically shows. 


“Real Time Prescription Monitoring is now available and must be used by health professionals to have non-judgemental conversations with people about the potential risks associated with medicines – and particularly when multiple medicines are being used at the same time. RTPM is making an impact but is not the whole answer. More solutions are needed. 


“As health professionals, we need to expand the way we assess risk. We need to recognise that medicine sharing happens and should form a routine part of all patient conversations about risk.  


“We need to offer Take Home Naloxone routinely and repeatedly to any person at-risk of experiencing or witnessing opioid overdose, and to people taking other medicines in combination with prescribed or illicit opioids.” 


Dr Sim called for more support for our health workforce to have conversations with potentially at-risk individuals in a meaningful, non-judgemental and supportive way, including by increasing access to training, guidelines, peer support and fostering collaboration of health teams. 


“Pharmacists work with at-risk individuals every day, but need better funding and support to be able to make a meaningful impact in reducing death and injury which drug overdose can cause. This includes building workforce capacity to be more active in deprescribing roles, particularly in primary care,” she said. 


“Pharmacists are the custodians of safe use of medicines, we are the key to reducing medicine-related harm. Pharmacists should be empowered and supported to do more to prevent medicine-related harm.   


“Every unintentional medicine-related harm is a failure of our health system. There is clearly more work to be done. I commend the Pennington Institute for producing this annual report, and for its impact over the previous eight years.” 


Media contact:   Georgia Clarke   M: 0480 099 798  E: georgia.clarke@psa.org.au

Pharmacists can deliver on current and future challenges

25 August 2023


Following the release of the Australian Government’s Intergenerational Report 2023, the Pharmaceutical Society of Australia (PSA) has called for pharmacists to be able to do more to support the country’s increased healthcare needs as our population ages.


The report, released yesterday, highlights five major factors affecting public policy moving forward. In particular, the report acknowledges that Australia’s ageing population and rising demand for care and support services will add further pressure on our already strained health system, hospital emergency departments, and further exacerbate wait times in General Practice.


PSA National President Dr Fei Sim FPS said the report highlighted both the urgent and the long-term need for pharmacists in all practice areas to work to their top of scope.


“The Federal Government’s Intergenerational Report confirmed that our gaining population will continue to have a significant impact on the Australian economy,” she said.


“Combined with the rising demand for quality health care services, we must be able to ensure the long-term sustainability of our health system.


“Access to care is a growing issue in Australia, and the situation is exacerbated in rural and remote communities.


“Australians need all health professionals working to their top of scope – including pharmacists.”


The Federal Government also announced yesterday that ANU’s Professor Mark Cormack will lead the Unleashing the Potential of our Health Workforce Review, to be delivered in 2024.


“The government’s scope of practice review needs to heed the warnings of the Intergenerational report and unlock the potential of our health workforce using pharmacists,” Dr Sim said.


“Pharmacists are highly trained health professionals and should be supported to practise to full scope, contributing to sustainability of our health system to enable equitable access to healthcare by all Australians.


“There are a range of common ailments which can be safely and effectively managed by pharmacists, supported by international evidence, facilitating safe and timely care.


“This can only be achieved with meaningful investment and funding to empower pharmacists to deliver important health care to Australians.


“Pharmacists can, and should, play a significant role to improve Australian’s access to care, and contribute towards quality, safe and effective use of medicines in all parts of the healthcare system.


“On behalf of Australian pharmacists, I look forward to working with Professor Cormack and his team on the Unleashing the Potential of our Health Workforce Review,” Dr Sim concluded.


The Federal Government’s Intergenerational Report is available here.



Media contact:   Georgia Clarke   M: 0480 099 798  E: georgia.clarke@psa.org.au

Renewed partnership to enhance support for pharmacy students

24 August 2023



The Pharmaceutical Society of Australia (PSA) and the National Australian Pharmacy Students’ Association (NAPSA) have reaffirmed their longstanding partnership to enhance support for pharmacy students at 18 universities across Australia.


The renewed Memorandum of Understanding (MOU) ensures that students are supported throughout their studies and professional development.


PSA National President Dr Fei Sim FPS recognises the importance of supporting pharmacy students as the future of the profession.


“PSA has a long and proud history of supporting pharmacy students, who make up a vital part of our profession and PSA’s membership,” Dr Sim said.


“Our role is to ensure that our profession has a vibrant and strong future, and that our members have rewarding and exciting career pathways.


“Through our partnership with NAPSA, we are giving pharmacy students around Australia the opportunity to engage with the broader profession, having their voices heard on the issues that affect them and their futures.


“As the peak body representing pharmacists in all practice settings, we are supporting future pharmacists to help shape their profession.


“We are proud to continue to support the vital role of NAPSA and pharmacy students,” Dr Sim concluded.


NAPSA President Bano Serhan said the renewed agreement “will continue to provide students with the best opportunities to engage in a professional environment alongside their education.


“NAPSA’s members are best served by our close relationships with industry organisations, and with the keen interest of the new Board in policy and advocacy, I am looking forward to the year ahead working closely with the PSA.


“Pharmacy students know they have NAPSA and PSA in their corner, and this renewed agreement will continue that tradition.


“Supporting future pharmacists will cement our industry as the leading primary healthcare service in Australia.”



Media contact:   Georgia Clarke   M: 0480 099 798      E: georgia.clarke@psa.org.au

Tribute to FIP President, the late Dominique Jordan

20 August 2023


The Pharmaceutical Society of Australia (PSA) is today paying tribute to International Pharmaceutical Federation (FIP) President Mr Dominique Jordan, who sadly passed away overnight.


Dominique shared news of his cancer diagnosis in July 2022 and had been undergoing treatment since.


A Swiss community pharmacist, Dominique became a member of FIP 20 years ago. In his home country, his actions to advance pharmacy included roles as president and CEO, concurrently, of pharmaSuisse, the Swiss association of pharmacists.


Dominique was elected president of FIP in 2018. Before that, he served FIP and global pharmacy as chair of the Board of Pharmaceutical Practice (2014-2018).


PSA National President Dr Fei Sim FPS paid tribute to Mr Jordan.


“Despite his ongoing battle with cancer, Dominique always captured the tenacity and positivity in life,” Dr Sim said.


“Dominique has worked tirelessly and given much of his life to professional pharmacy both in Australia and internationally and leaves a huge legacy to the profession. He will be greatly missed.


“On behalf of Australian pharmacists, PSA offers our deepest condolences to Mr Jordan’s friends, family, and colleagues.”


As per FIP Statutes (article 16.13), president-elect Paul Sinclair AM MPS will begin his term effective immediately.





Media contact:   Georgia Clarke   M: 0480 099 798  E: georgia.clarke@psa.org.au


8CPA negotiations to begin a year ahead of schedule

8 August 2023


The PSA welcomes the Federal Government’s announcement that early negotiations for the 8th Community Pharmacy Agreement (CPA) will begin as soon as possible, whilst highlighting the need to secure the short-term viability of the community pharmacy sector.


Federal Minister for Health and Aged Care Mark Butler MP has said the Pharmaceutical Society of Australia (PSA) and the Pharmacy Guild of Australia will continue to be signatories to any new agreement, with negotiations set to conclude by the end of the 2023-24 financial year.


PSA National President Dr Fei Sim FPS said that negotiations for 8CPA must harness community pharmacists as the solution to Australia’s primary care crisis – but emphasised immediate and long-term viability risks could make this difficult to achieve.


“PSA looks forward to working with the government and the Pharmacy Guild to drive better and safer access to medicines for Australians,” Dr Sim said.


“We need to do more to reduce the preventable harm medicines are causing in Australia. Up to half of the 250,000 medicine-related hospital admissions per year in Australia are preventable.


“More Australians are finding it more difficult to access their essential medicines due to waiting times to access their regular prescribers. These are real problems PSA will seek solutions for during the 8CPA negotiations.


“The new agreement should enable pharmacists to practice to full scope. This agreement should deliver better access to care for all Australians by cementing the core role of pharmacists as the stewards for safe and effective use of medicines.”


“As the peak body representing pharmacists in Australia, and as steward of professional standards, PSA is committed to working constructively and collaboratively during this process of negotiation to deliver the outcome which includes better ways for pharmacists to show the impact of the care they provide.


“PSA has championed embedding of quality and safety measures in pharmacy programs for many years, and will seek to drive evaluation measures in CPA programs to help demonstrate the role pharmacists play every day in supporting safer and more effective use of medicines.


“While there is up to 11 months before negotiations are proposed to conclude, the real impact of 60-day dispensing will be felt immediately by community pharmacists as the measure commences on 1 September. We must ensure close alignment between the commencement of 60-day dispensing and the commencement of a new community pharmacy agreement.


“Pharmacists need certainty now that the care they provide will remain viable in the short term.


“As a profession, pharmacists can do more and want to do more. But we can’t keep doing more with less.”


Media contact:   Georgia Clarke   M: 0480 099 798  E: georgia.clarke@psa.org.au

WA women to have access to UTI care through pharmacists

4 August 2023


The Pharmaceutical Society of Australia (PSA) welcomes the West Australian Government’s commitment to improving access to care for thousands of women suffering from urinary tract infections each year.


From today, 4 August 2023, pharmacists who have undergone specific training will be able to prescribe antibiotics for uncomplicated urinary tract infections (UTIs) in patients aged 18 to 65 years old. The training is now available to all WA pharmacists.


PSA Western Australia President Kristian Ray welcomed the move, saying that patient’s access to care should be front of mind.


“Pharmacists are well positioned to play a greater role in primary health care and will make UTI treatments more accessible for more West Australians,” Mr Ray said.


“There are hundreds of thousands of women living in Western Australia that will benefit from this policy, particularly in rural and remote WA where there are significant barriers to accessing timely care.


“This program is about improving access to care where it is clinically appropriate, and working with the rest of the primary care team to promote a collaborative care model for Western Australians.


“There are robust referral pathways in place for patients who suffer from recurring UTIs, or might fall outside of the clinical inclusion criteria.


“As some of the most accessible healthcare professionals, pharmacists play a vital role in supporting the health and wellbeing of our communities.


“As pharmacists, we are committed to working collaboratively with the entire health sector to deliver best outcomes for patients.


“I am looking forward to working closely with the Government to ensure the success of the program, improving access to safe, timely care,” Mr Ray concluded.


The PSA training program Managing Uncomplicated Cystitis (Urinary Tract Infection) is now available to all WA pharmacists. More information is available here.


Media contact:   Georgia Clarke   M: 0480 099 798  E: georgia.clarke@psa.org.au

New Fellows recognised at PSA23

4 August 2023


The Pharmaceutical Society of Australia (PSA) has announced 11 new Fellows in recognition of their outstanding and sustained contribution to PSA and the pharmacy profession.


PSA National President Dr Fei Sim FPS congratulated PSA members who were recognised for their significant advancement and achievement in the practice of pharmacy over an extended period of time.


“Each of these pharmacists have made significant contributions to pharmacy, exemplifying the passion of our profession.


“Fellowships of PSA are a prominent acknowledgement of those who have provided an outstanding contribution to PSA or the profession for an extended period of time.


“On behalf of PSA, I thank them for their ongoing service and dedication to improving pharmacy practice and patient care.”


The 2023 PSA Fellows are:


Brad Butt FPS (ACT)

Brad Butt established Men’s Health Down Under from his pharmacy in 2013 to address the growing need for men in the ACT to have access to professional expertise without any embarrassment or privacy concerns.  It is highly innovative original service that supports people in a therapeutic area that is often shrouded in ignorance.


Men’s Health Downunder has grown to be the largest Men’s health pharmacy clinic in Australia, and now many patients are referred via GPs, urologists, and sexual health clinics as well as patients self-referring for additional service and advice.


Mr Butt has expanded the scope of pharmacist practice by establishing his own clinic in response to a gap in the support for men post prostatectomy and has grown the clinic to support many men across Australia. The impact of the program includes reducing stigma around the topic, and reduced depression in patients.  Providing patients and their partners support with their urological health issues has an immeasurably positive impact on patients.



Arthur Chistopoulos FPS (VIC)

Arthur Christopoulos is the Professor of Analytical Pharmacology and the Dean of the Faculty of Pharmacy & Pharmaceutical Sciences at Monash University. Prior to his appointment as Dean, he was a Senior Principal Research Fellow of the National Health and Medical Research Council of Australia. His research focuses on novel paradigms of drug action at G protein-coupled receptors (GPCRs), the largest drug target class for modern medicines, and incorporates computational and mathematical modelling, structural and chemical biology, molecular and cellular pharmacology, medicinal chemistry, and preclinical models of behaviour and disease. His work has been applied studies encompassing neurological and psychiatric disorders, cardiovascular disease, obesity, diabetes, chronic pain and addiction, and he has received substantial, long-term support from international and national competitive, charitable and commercial sources.


In 2022, together with Profs. Robert J. Lefkowitz and Patrick Sexton, Prof. Christopoulos was an academic co-founder of Septerna Inc., a novel GPCR biotechnology company. Professor Christopoulos has over 360 publications, has served on the Editorial Board of 8 international journals and was a Councillor of the International Union of Basic and Clinical Pharmacology (IUPHAR).



Jeni Diekman FPS (NSW)

Jeni Diekman has championed professional pharmacy practice throughout her career across hospital pharmacy, academia, corporate healthcare and as a community pharmacy owner of 20 years. As a community pharmacist, Jeni has shown significant leadership to promote and advocate for pharmacists, including increased involvement in professional services and better remuneration.


Ms Diekman is a member of the leadership group of the PSA Contemporary Community Pharmacy Community of Specialty Interest, a group whose aim is to identify where further support is required for community pharmacists as the face massive organisational, economic and technological change.  Jeni works to implement the recommendations of the PSA-CSI Contemporary Community Pharmacy Practice White Paper.


Ms Diekman is passionate about self-care, and was involved in the creation of the PSA self-care program as a PSA employee, and currently advocates for an improved self-care program to assist pharmacists in delivering more effective healthcare.



Chelsea Felkai FPS (NSW)

Cheslea Felkai served as PSA NSW President from 2020 to 2023.  Throughout the pandemic, Chelsea led NSW pharmacists by advocating for regulatory change and expanded scope of practice, especially including pharmacists in the COVID-19 vaccine roll out in 2021.


Ms Felkai has also advocated for improved access to medicines for patients in emergency situations, minor ailments services, embedded aged care pharmacists and advocating and highlighted medicines related issues for those with disability.


The impact has been widespread across the profession, with the number of vaccines pharmacists can administer expanding across many jurisdictions, including in NSW.


Ms Felkai is still currently advocating through the Department of Health and State Government to improve medicines management for patients with disability.  She is currently undertaking a PhD at the University of Newcastle around medicine safety for people with disability.



Sarah Gillespie FPS (ACT)

Over many years, Sarah Gillespie has been a mentor and advocate for the consultant pharmacy profession through both the Australian Association of Consultant Pharmacy (AACP) and PSA.


Despite her busy role and schedule, she has always made herself available to listen with empathy, humanity, and professionalism. Accredited pharmacists face a challenging and changing role and have benefited from her support and careful guidance in an apolitical way. Sarah has listened and supported many accredited pharmacists over the years, particularly during significant changes to the accredited pharmacist role.


Ms Gillespie has served the profession through providing regular clinical updates in a newsletter, planning and executing consultant pharmacist conferences, and developing protocols and guidelines for accredited pharmacists. Her support through the transitions and uncertainty over the past year have been particularly valuable to accredited pharmacists.



Robyn Johns FPS (SA/NT)

Robyn Johns has been a dedicated member of PSA SA/NT Branch for a vast majority of her community pharmacy career. Robyn’s contribution to pharmacy profession has been truly outstanding, especially during her time when she served the profession as PSA SA/NT Branch President. During her time as Branch President, she demonstrated dedication, leadership, and excellence.


Ms Johns’ contribution has been instrumental in SA community pharmacy’s sector’s COVID-19 response. Her collaboration on this matter with South Australian’s Department for Health and Wellbeing officials significantly and positively influenced community pharmacy processes’ development and subsequent smooth implementation, as well as extension of vaccinations for pharmacists as part of the NIP access.


In addition, Ms Johns’ input was instrumental to the commencement of Real Time Prescription Monitoring in South Australia, where she contributed significantly with her skills and time to the launch of this initiative.  She further served as a Controlled Substances Advisory Council member, where her expertise saw a significant contribution to the changes the legislation.



Professor Faye McMillan AM FPS (NSW)

Professor Faye McMillan is Australia’s first registered Aboriginal pharmacist. Professor McMillan’s passion and continued effort has made significant contribution to improving people’s health and wellbeing. Her work has led to a paradigm shift in the way Aboriginal and Torres Strait Islander people seek and access healthcare in Australia.


Professor McMillan is an inspiration to many, and a role model for all pharmacists, all women and the Indigenous people of Australia. She was instrumental in the Closing the Gap Steering Committee since 2013, which has led to a paradigm shift in the way Aboriginal and Torres Strait Islander people seek and access healthcare. One of Prof. McMillan’s main passions involves the recruitment and retention of Aboriginal and Torres Strait Islander people into allied health professions.



Dr Sandra Salter FPS (WA)

Dr Sandra Salter is a highly successful allergy and anaphylaxis researcher, was the first pharmacist member of the Australasian Society of Clinical Immunology and Allergy and has won international conference prizes for her pharmacy practice anaphylaxis research. She is equally a highly successful innovator and was awarded the flagship 2021 UTS Innovative Pharmacist of the Year Award for her world-leading innovation in active vaccine surveillance from pharmacies.


Dr Salter’s work on active vaccine surveillance has impacted every pharmacy and pharmacist that provides vaccinations. It has expanded scope of practice within the types of vaccines pharmacists can deliver, proven pharmacist vaccinators are safe, and enabled consumers to have even greater confidence in obtaining a vaccine from a pharmacy.



Andrew Sluggett FPS (SA/NT)

Andrew Sluggett has contributed to the significant advancement of the pharmacy profession through seeing and progressing enhanced pharmacy care in transforming community pharmacy into a bespoke health hub, benefiting both pharmacists and patients in South Australia. He has also developed compounding dispensing software, patented and commercialised a new infusion device for use in hospital settings.


Through these innovations, Mr Sluggett has significantly contributed to more effective, collaborative, and safer pharmacy practice. His research contributions have demonstrated dedication and innovative thinking, which motivate many young and early career pharmacists in South Australia to take on the research path while working in community or hospital pharmacy settings.


Mr Sluggett has more than 17 years of service as an elected SA/NT Branch Committee member, including six years as co-vice president. He has served on the PSA National Board for more than three years, as well as on the Board of the Australian Medicines Handbook. During this time, he has championed the work of PSA and passionately advocated for our profession through contributions as Chair (Standards Review Group 2022-23, CPD Committee 2016) and member of national working groups (Membership 2010-14, ECPs 2009, CPD and Practice Committees 2006-16), all of which have led to tangible benefits for PSA members and the wider profession.



Dr Natalie Soulsby FPS (SA/NT)

Dr Natalie Soulsby has spent the last 8 years as Head of Clinical Development for a team of 40+ clinical pharmacists working in aged care. Through this, she has contributed to defining and expanding the role of pharmacists working in aged care facilities which has contributed to the announcement of Government funding for on-site aged care pharmacists.


Through her role as Clinical Manager at Ward MM Dr Soulsby has drawn on her previous research and hospital pharmacy experience to improve clinical governance in the aged care facilities that Ward MM provides services to. Dr Soulsby has developed cohesive relationships with aged care partners and as a consequence of this is a member of several National Clinical Governance Committees and National Medication Advisory Committees for large aged are provider groups. Further, Dr Soulsby set up the clinical governance framework at WardMM.


Since been working in the aged care sector, Dr Soulsby has published a range of articles highlighting the role of pharmacists in ensuring medicine safety. These articles are practical and widely read by aged care pharmacists but also a range of members in the interdisciplinary team around the older person.



Dr Andrew Stafford FPS (WA)

Dr Andrew Stafford has dedicated his career to expanding the role of pharmacist practice in aged care and dementia care, particularly in interdisciplinary teamwork. Of particular note is his work within Dementia Training Australia, where he was the first pharmacist to act in a Director role. In this position, Dr Stafford worked to expand other health professions’ understanding of the skills and capabilities of pharmacists in aged and dementia care settings and led the development and delivery of a program of work to promote pharmacists across the country.


Dr Stafford has contributed to several publications, including the Australian Pharmaceutical Formulary, and PSA’s Guidelines for Comprehensive Medication Management Reviews, Quality Use of Medicines and Digital Health. As the foundations for many areas of pharmacy practice, it is indisputable that Dr Stafford’s contribution has shaped practice across Australia.


The medication management resources Dr Stafford developed during through his work at Dementia Training Australia are used nation- wide, further demonstrating the impact of his work. These resources, which outline the appropriate use of psychotropic medications in aged care, assist pharmacists working in these areas to improve medicines safety for some of the most vulnerable and neglected Australians.



Media contact:   Georgia Clarke   M: 0480 099 798  E: georgia.clarke@psa.org.au